<DOC>
	<DOC>NCT01436214</DOC>
	<brief_summary>This study is a phase 1/2a, open label, dose escalation and safety study of APC-100 (2,2,5,7,8-Pentamethyl-6-chromanol) in men with advanced prostate cancer.</brief_summary>
	<brief_title>Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patients with histopathologically proven adenocarcinoma of the prostate Patients must have progressive disease Patients must have had prior treatment with bilateral orchiectomy or androgen deprivation therapy with an LHRHblocker with evidence of treatment failure Patients treated with other secondary hormonal therapies Patients with prior chemotherapy given for castrateresistant prostate cancer Patients with prior radiation therapy completed less than 4 weeks prior enrollment Patients with prior investigational therapies within 4 weeks before treatment with APC100 Evidence of active second malignancy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>